733 related articles for article (PubMed ID: 32709610)
21. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
22. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
23. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
[TBL] [Abstract][Full Text] [Related]
24. Effects of nintedanib on the microvascular architecture in a lung fibrosis model.
Ackermann M; Kim YO; Wagner WL; Schuppan D; Valenzuela CD; Mentzer SJ; Kreuz S; Stiller D; Wollin L; Konerding MA
Angiogenesis; 2017 Aug; 20(3):359-372. PubMed ID: 28283856
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of the stem cell factor 248 isoform attenuates the development of pulmonary remodeling disease.
Rasky A; Habiel DM; Morris S; Schaller M; Moore BB; Phan S; Kunkel SL; Phillips M; Hogaboam C; Lukacs NW
Am J Physiol Lung Cell Mol Physiol; 2020 Jan; 318(1):L200-L211. PubMed ID: 31747308
[TBL] [Abstract][Full Text] [Related]
26. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
27. Tissue and Bronchoalveolar Lavage Biomarkers in Idiopathic Pulmonary Fibrosis Patients on Pirfenidone.
Ronan N; Bennett DM; Khan KA; McCarthy Y; Dahly D; Bourke L; Chelliah A; Cavazza A; O'Regan K; Moloney F; Plant BJ; Henry MT
Lung; 2018 Oct; 196(5):543-552. PubMed ID: 30066212
[TBL] [Abstract][Full Text] [Related]
28. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
[TBL] [Abstract][Full Text] [Related]
29. Dual inhibition of α
Decaris ML; Schaub JR; Chen C; Cha J; Lee GG; Rexhepaj M; Ho SS; Rao V; Marlow MM; Kotak P; Budi EH; Hooi L; Wu J; Fridlib M; Martin SP; Huang S; Chen M; Muñoz M; Hom TF; Wolters PJ; Desai TJ; Rock F; Leftheris K; Morgans DJ; Lepist EI; Andre P; Lefebvre EA; Turner SM
Respir Res; 2021 Oct; 22(1):265. PubMed ID: 34666752
[TBL] [Abstract][Full Text] [Related]
30. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
31. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry.
Holtze CH; Freiheit EA; Limb SL; Stauffer JL; Raimundo K; Pan WT; Flaherty KR; Kim HJ
Respir Res; 2020 Feb; 21(1):48. PubMed ID: 32041621
[TBL] [Abstract][Full Text] [Related]
32. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis.
Epstein Shochet G; Bardenstein-Wald B; McElroy M; Kukuy A; Surber M; Edelstein E; Pertzov B; Kramer MR; Shitrit D
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805152
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
Kim JS; Murray S; Yow E; Anstrom KJ; Kim HJ; Flaherty KR; Martinez FJ; Noth I
Chest; 2024 May; 165(5):1163-1173. PubMed ID: 38030064
[TBL] [Abstract][Full Text] [Related]
35. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
[TBL] [Abstract][Full Text] [Related]
36. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
37. The efficacy of pirfenidone in a sheep model of pulmonary fibrosis.
Dewage SNV; Organ L; Koumoundouros E; Derseh HB; Perera KUE; Samuel CS; Stent AW; Snibson KJ
Exp Lung Res; 2019; 45(9-10):310-322. PubMed ID: 31762329
[TBL] [Abstract][Full Text] [Related]
38. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
Flaherty KR; Fell CD; Huggins JT; Nunes H; Sussman R; Valenzuela C; Petzinger U; Stauffer JL; Gilberg F; Bengus M; Wijsenbeek M
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946005
[TBL] [Abstract][Full Text] [Related]
39. MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis.
Boehme SA; Franz-Bacon K; DiTirro DN; Ly TW; Bacon KB
PLoS One; 2016; 11(5):e0154874. PubMed ID: 27144281
[TBL] [Abstract][Full Text] [Related]
40. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
